Atlas Venture Life Science Advisors
CAMBRIDGE, MAfiles as Atlas Venture Life Science Advisors, LLC
$881m in 7 US stocks at the end of 30 June 2026. The top 10 are 100.0% of the money. It changed about 15.5% of the portfolio this quarter.
Value
$881m
Stocks
7
Top 10 share
100.0%
Turnover
15.5%
What changed this quarter
New
Bought for the first time this quarter.
- Kailera TherapeuticsKLRA12.9% of the fund
Added
Bought more of a stock they already held.
- Q32 BioQTTB3.9% of the fund+30%
Cut
Sold some of their stake.
- Kymera TherapeuticsKYMR37.1% of the fund-38%
- Dyne TherapeuticsDYN17.1% of the fund-26%
- Korro BioKRRO1.4% of the fund-15%
Sold out
Sold their entire stake.
None this quarter.
Holdings
- Kailera TherapeuticsKLRA
- Share
- 12.9%
- Value
- $114m
- Shares
- 5,171,282
New
| Company | Share of fund | Value | Shares | Change |
|---|---|---|---|---|
| Kymera TherapeuticsKYMR | 37.1% | $327m | 2,847,541 | -38% |
| Dyne TherapeuticsDYN | 17.1% | $151m | 6,800,099 | -26% |
| Sionna TherapeuticsSION | 15.0% | $132m | 2,995,602 | Held |
| Kailera TherapeuticsKLRA | 12.9% | $114m | 5,171,282 | New |
| Disc MedicineIRON | 12.6% | $111m | 1,513,875 | Held |
| Q32 BioQTTB | 3.9% | $35m | 2,717,106 | +30% |
| Korro BioKRRO | 1.4% | $13m | 962,884 | -15% |
Over time and by industry
Value over time
Jun '25
Dec '25
Jun '26
Value is up 33.1% since 30 June 2025.
Where the money is
Health care100.0%
From the fund's 13F filings. They list US stocks and options only, 45 days after each quarter, and leave out cash, bonds, shorts and foreign shares.